Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares > Rats fleeing the sinking ship
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by kuatoliveson May 25, 2017 7:12pm
216 Views
Post# 26285679

RE:RE:RE:RE:Rats fleeing the sinking ship

RE:RE:RE:RE:Rats fleeing the sinking shipHarris has no business being on the board either, given how badly he sold-out his shareholders, yet there he is. We're trying to help you bigerr (and others); take your lumps and get out. The interest on the debt alone will total 25% of the anual gross this year. Yosprala is a flop and they're pinning their hopes on a drug that was already deemed to be a flop once already. Directors are selling their shares. Jeez, what more do you need? You've got a better chance of a Valeant or Concordia doubleup than this thing ever seeing 3 bucks again.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities